Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cytek Biosciences (CTKB)
NASDAQ:CTKB
Holding CTKB?
Track your performance easily
CTKB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.66 - $9.87
Previous Close$6.69
Volume277.96K
Average Volume (3M)691.06K
Market Cap
$826.96M
Enterprise Value$592.96M
Total Cash (Recent Filing)$277.78M
Total Debt (Recent Filing)$8.99M
Price to Earnings (P/E)―
Beta2.44
Next Earnings
Feb 26, 2025EPS Estimate
$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding128,810,614
10 Day Avg. Volume889,475
30 Day Avg. Volume691,062
Standard Deviation0.19
R-Squared0.12
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.05
Price to Sales (P/S)3.92
Price to Cash Flow (P/CF)14.90
P/FCF Ratio16.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit5.42
Enterprise Value/Ebitda-129.81
Forecast
1Y Price Target
$8.75Price Target Upside36.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Cytek Biosciences News
PremiumCompany Announcements
Cytek Biosciences’ Q3 2024 Financial Highlights
PremiumCompany Announcements
Cytek Biosciences COO Resigns, Signaling Leadership ChangesBulls Say, Bears Say
Bulls Say
Cash Flow And ProfitabilityCytek reiterated their expectations for FY24 positive cash flow from operations as they march towards consistent profitability.
Market RecoveryManagement highlighted positive early signs of recovery in the US instrument market, which negatively impacted Q2 results, accredited to biotech market improvement.
Product PerformanceAPAC and EMEA end markets are performing well, and new products should also help keep this outperformance consistent.
Bears Say
Financial GuidanceFY24 net income guide was lowered.
Market ExpectationsMarket recovery is not on pace with management's expectations.
Sales PerformanceA modest top-line miss driven by U.S. instrument sales softness offsets stronger Service contributions.
---
Ownership Overview
9.22% Insiders
16.65% Mutual Funds
14.34% Other Institutional Investors
37.60% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CTKB FAQ
What was Cytek Biosciences’s price range in the past 12 months?
Cytek Biosciences lowest stock price was $4.66 and its highest was $9.87 in the past 12 months.
What is Cytek Biosciences’s market cap?
Currently, no data Available
When is Cytek Biosciences’s upcoming earnings report date?
Cytek Biosciences’s upcoming earnings report date is Feb 26, 2025 which is in 92 days.
How were Cytek Biosciences’s earnings last quarter?
Cytek Biosciences released its earnings results on Nov 05, 2024. The company reported $0.063 earnings per share for the quarter, beating the consensus estimate of $0.012 by $0.051.
Is Cytek Biosciences overvalued?
According to Wall Street analysts Cytek Biosciences’s price is currently Undervalued.
Does Cytek Biosciences pay dividends?
Cytek Biosciences does not currently pay dividends.
What is Cytek Biosciences’s EPS estimate?
Cytek Biosciences’s EPS estimate is $0.11.
How many shares outstanding does Cytek Biosciences have?
Cytek Biosciences has 128,810,610 shares outstanding.
What happened to Cytek Biosciences’s price movement after its last earnings report?
Cytek Biosciences reported an EPS of $0.063 in its last earnings report, beating expectations of $0.012. Following the earnings report the stock price went up 36.029%.
Which hedge fund is a major shareholder of Cytek Biosciences?
Among the largest hedge funds holding Cytek Biosciences’s share is Royce & Associates LLC. It holds Cytek Biosciences’s shares valued at 1M.
---
Cytek Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.75 (36.29% Upside)
$8.75 (36.29% Upside)
Blogger Sentiment
Bullish
CTKB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.29%
12-Months-Change
Fundamentals
Return on Equity
-2.54%
Trailing 12-Months
Asset Growth
-5.43%
Trailing 12-Months
Company Description
Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Aurora and Northern Lights systems, are the first full spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells.
---
CTKB Earnings Call
Q3 2024
0:00 / 0:00
---
CTKB Stock 12 Month Forecast
Average Price Target
$8.75
▲(36.29% Upside)
Technical Analysis
Best Analysts Covering CTKB
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-13.43%
reiterated a buy rating 4 months ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -13.43% per trade.
---